Abstract
Malignant gliomas are common primary tumors of the central nervous system, characterized by aggressive cell proliferation, diffuse infiltration and resistance to conventional therapy. Glioblastoma (former Glioblastoma multiforme, GBM), grade IV astrocytoma, is the most aggressive tumor, with a median survival of around 14 months. New therapies against this devastating and invariably fatal disease are needed. Stem-like cell populations have been identified in a number of malignancies including glioblastoma. These rare stem cells (called also glioma-initiating cells) are believed to be responsible not only for tumor initiation and progression but also resistance to therapeutic agents and tumor recurrence. Recently, the population of cells within glioblastoma with stem-like properties has gained increasing attention as a target to refine treatment strategies. This chapter aims to summarize the recent data regarding isolation, biology and mechanisms of resistance of glioblastoma stem-like cells to therapy.
Keywords: Glioblastoma, glioma-initiating cells (GIC), glioma stem cells (GSC), functional characteristics, isolation, markers, therapeutic resistance.
Current Signal Transduction Therapy
Title:Glioblastoma Stem-Like Cells – Isolation, Biology and Mechanisms of Chemotherapy Resistance
Volume: 8 Issue: 3
Author(s): Iwona Anna Ciechomska, Marta Kocyk and Bozena Kaminska
Affiliation:
Keywords: Glioblastoma, glioma-initiating cells (GIC), glioma stem cells (GSC), functional characteristics, isolation, markers, therapeutic resistance.
Abstract: Malignant gliomas are common primary tumors of the central nervous system, characterized by aggressive cell proliferation, diffuse infiltration and resistance to conventional therapy. Glioblastoma (former Glioblastoma multiforme, GBM), grade IV astrocytoma, is the most aggressive tumor, with a median survival of around 14 months. New therapies against this devastating and invariably fatal disease are needed. Stem-like cell populations have been identified in a number of malignancies including glioblastoma. These rare stem cells (called also glioma-initiating cells) are believed to be responsible not only for tumor initiation and progression but also resistance to therapeutic agents and tumor recurrence. Recently, the population of cells within glioblastoma with stem-like properties has gained increasing attention as a target to refine treatment strategies. This chapter aims to summarize the recent data regarding isolation, biology and mechanisms of resistance of glioblastoma stem-like cells to therapy.
Export Options
About this article
Cite this article as:
Ciechomska Anna Iwona, Kocyk Marta and Kaminska Bozena, Glioblastoma Stem-Like Cells – Isolation, Biology and Mechanisms of Chemotherapy Resistance, Current Signal Transduction Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/1574362409666140206223501
DOI https://dx.doi.org/10.2174/1574362409666140206223501 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
DNA-Based Methods to Prepare Helper Virus-Free Herpes Amplicon Vectors and Versatile Design of Amplicon Vector Plasmids
Current Gene Therapy Matrix Metalloproteinases: Drug Targets for Myocardial Infarction
Current Drug Targets Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Functional Evaluation of Neural Stem Cell Differentiation by Single Cell Calcium Imaging
Current Stem Cell Research & Therapy The Smart Targeting of Nanoparticles
Current Pharmaceutical Design Liposomes: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Serum Carboxypeptidase N1 Serves as a Potential Biomarker Complementing CA15-3 for Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?
Current Medicinal Chemistry Next Generation Antineoplastic Agents: A Review on Structurally Modified Vinblastine (VBL) Analogues
Current Medicinal Chemistry Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy
Current Cancer Drug Targets Endothelial Progenitor Cells: Hope Beyond Controversy
Current Cancer Drug Targets Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research Nucleic Acid Aptamers Against Protein Kinases
Current Medicinal Chemistry Antibody Targeting of TGF-β in Cancer Patients
Current Pharmaceutical Biotechnology MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry Nanostructures for Bypassing Blood Brain Barrier
Current Bioactive Compounds Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents
Current Medicinal Chemistry Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Biological Activity Evaluation of Novel 1,2,4-Triazine Derivatives Containing Thiazole/Benzothiazole Rings
Anti-Cancer Agents in Medicinal Chemistry HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued)